Aim Bulletin
Renalytix shares more than double after striking US diagnostics partnership
By Iain Gilbert
Date: Monday 15 Sep 2025
(Sharecast News) - Medical diagnostics firm Renalytix said on Monday that it has struck a definitive agreement with Tempus AI to accelerate the adoption of its kidneyintelX.dkd test to support early-stage risk assessment in chronic kidney disease, slow progression, and improve patient outcomes.
Renalytix said the collaboration will make kidneyintelX.dkd prognostic blood testing more widely available for eligible patients within its US network of healthcare institutions. Eligible patients have type two diabetes with chronic kidney disease, impacting nearly 15m individuals in the US.
The AIM-listed firm's kidneyintelX.dkd will be the first test offered in Tempus' portfolio in the chronic kidney disease category, indicated for use as an aid in predicting the level of risk for progressive decline in kidney function in type two diabetes patients with diagnosed chronic kidney disease stages 1-3b.
Chief executive James McCullough said: "The unique Tempus platform, with its broad clinical reach, will allow us to significantly expand patient and clinician access to advanced kidneyintelX.dkd precision medicine testing in one of the largest and costliest chronic disease conditions today.
"Further, we expect our partnership to be instrumental in driving therapeutic and diagnostic innovation through multi-modal data accumulation and analysis in patients in the cardiovascular, renal and metabolic space."
As of 0925 BST, Renalytix shares had skyrocketed 105.98% to 12.05p.
Reporting by Iain Gilbert at Sharecast.com
Article Archive
Free Membership To Digital Look
Discover the full range of Investor's Tools and Services from Digital Look - voted 'Best Research & Information Provider 2007' by Investors Chronicle.
En HeaderFooterDLYou are here: research